Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome
Primary Purpose
Choroidal Neovascularization, Presumed Ocular Histoplasmosis
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
EYLEA (Aflibercept) intravitreal injection
Sponsored by
About this trial
This is an interventional treatment trial for Choroidal Neovascularization
Eligibility Criteria
Inclusion Criteria:
- CNV of less than 1 year duration due to presumed ocular histoplasmosis
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Age 21 years and older
- Subfoveal or juxtafoveal CNV lesion of less than 5400um in diameter
- Best corrected visual acuity of 20/25 to 20/400
- Birth control therapy for females of child-bearing age
Exclusion Criteria:
- CNV due to presumed ocular histoplasmosis for greater than 1 year
- Pregnancy (positive pregnancy test) or lactation
- Premenopausal women not using adequate contraception. The following are considered effective means of contraception : surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch
- A recent history of smoking (within 1 year of study enrollment)
- Prior treatment with intravitreal aflibercept injection
- Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
- Uncontrolled glaucoma in the study eye (defined as IOP greater or equal to 30 mmHg despite treatment with anti-glaucoma medication)
- History of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment
- Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
- Presence of significant subfoveal fibrosis or atrophy
- Intraocular surgery (including cataract surgery) in the study eye within 2 months of enrollment
- Active intraocular inflammation (grade trace or above) in the study eye
- History of allergy to fluorescein, ICG or iodine, not amendable to treatment
- Any concurrent intraocular condition in the study eye (e.g., cataract or diabetic retinopathy) that, in the opinion of the investigator, could either
- Require medical or surgical intervention during the 12 month study period to prevent or treat visual loss that might result from that condition, or
- If allowed to progress untreated, could likely contribute to loss of at least 2 snellen equivalent lines of BCVA over the 12 month study period
- Prior/Concomitant Treatment:
- Panretinal photocoagulation treatment
- Previous intraocular steroids or PDT within 3 months
- Previous participation in any studies of investigational drugs within 30 days preceding Day 0 (excluding vitamins and minerals)
- Previous treatment with intravitreally (in either eye) or intravenously administered Avastin (bevacizumab) within 60 days
- Previous use of Macugen or Lucentis in study eye within 60 days
- Prior submacular or vitreous surgery
Sites / Locations
- The Retina Institute
- The Retina Institute
- The Retina Institute
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
IVT injection once every 8 weeks after 3 initial monthly doses
Arm Description
Intravitreal aflibercept injection 2.0mg dosed every 4 weeks (monthly)for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection every eight weeks (2 months). Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of greater than or equal to 5 letters from the previous visit.
Outcomes
Primary Outcome Measures
Safety
The Incidence & Severity will be assessed during study participation. Baseline medical conditions & abnormal findings present prior to the patient signing the Informed Consent Form (ICF)will be recorded as pre-existing illnesses in the medical history. Clinical study staff will start assessing subjects for adverse events once the ICF has been signed starting at month 1 and at each monthly visit,and will be instructed to request the adverse event information in a nonspecific, non-suggestive type of questioning. The Investigators will record all adverse events regardless of causality.
Secondary Outcome Measures
Mean visual acuity (BCVA) at Months 6 and 12
Mean change in OCT central foveal thickness from baseline at Months 6 and 12
Mean change in Macular Volume from baseline at Months 6 and 12
Mean change in visual acuity (BCVA) from baseline at Months 6 and 12
Mean change in CNV lesion characteristics (size, leakage, etc.) from baseline at Months 6 and 12
Proportion of patients with no fluid on OCT (absence of cystic edema and subretinal fluid) at Months 6 and 12
Full Information
NCT ID
NCT01578720
First Posted
April 2, 2012
Last Updated
August 27, 2018
Sponsor
Retina Research Institute, LLC
1. Study Identification
Unique Protocol Identification Number
NCT01578720
Brief Title
Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome
Official Title
Treatment of CNV Secondary to Presumed Ocular Histoplasmosis With EYLEA 2.0mg (Intravitreal Aflibercept Injection)
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
June 2012 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
March 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Retina Research Institute, LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to assess the efficacy and safety of intravitreal injection of aflibercept for the treatment of Choroidal Neovascularization (CNV) secondary to presumed ocular histoplasmosis syndrome (POHS).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Choroidal Neovascularization, Presumed Ocular Histoplasmosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Actual)
8. Arms, Groups, and Interventions
Arm Title
IVT injection once every 8 weeks after 3 initial monthly doses
Arm Type
Other
Arm Description
Intravitreal aflibercept injection 2.0mg dosed every 4 weeks (monthly)for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection every eight weeks (2 months).
Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of greater than or equal to 5 letters from the previous visit.
Intervention Type
Drug
Intervention Name(s)
EYLEA (Aflibercept) intravitreal injection
Intervention Description
Intravitreal Injection once every 8 weeks with 3 initial monthly doses
Primary Outcome Measure Information:
Title
Safety
Description
The Incidence & Severity will be assessed during study participation. Baseline medical conditions & abnormal findings present prior to the patient signing the Informed Consent Form (ICF)will be recorded as pre-existing illnesses in the medical history. Clinical study staff will start assessing subjects for adverse events once the ICF has been signed starting at month 1 and at each monthly visit,and will be instructed to request the adverse event information in a nonspecific, non-suggestive type of questioning. The Investigators will record all adverse events regardless of causality.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Mean visual acuity (BCVA) at Months 6 and 12
Time Frame
Month 6 and Month 12
Title
Mean change in OCT central foveal thickness from baseline at Months 6 and 12
Time Frame
Months 6 and 12
Title
Mean change in Macular Volume from baseline at Months 6 and 12
Time Frame
Months 6 and 12
Title
Mean change in visual acuity (BCVA) from baseline at Months 6 and 12
Time Frame
Months 6 and 12
Title
Mean change in CNV lesion characteristics (size, leakage, etc.) from baseline at Months 6 and 12
Time Frame
Months 6 and 12
Title
Proportion of patients with no fluid on OCT (absence of cystic edema and subretinal fluid) at Months 6 and 12
Time Frame
Months 6 and 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
CNV of less than 1 year duration due to presumed ocular histoplasmosis
Ability to provide written informed consent and comply with study assessments for the full duration of the study
Age 21 years and older
Subfoveal or juxtafoveal CNV lesion of less than 5400um in diameter
Best corrected visual acuity of 20/25 to 20/400
Birth control therapy for females of child-bearing age
Exclusion Criteria:
CNV due to presumed ocular histoplasmosis for greater than 1 year
Pregnancy (positive pregnancy test) or lactation
Premenopausal women not using adequate contraception. The following are considered effective means of contraception : surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch
A recent history of smoking (within 1 year of study enrollment)
Prior treatment with intravitreal aflibercept injection
Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
Uncontrolled glaucoma in the study eye (defined as IOP greater or equal to 30 mmHg despite treatment with anti-glaucoma medication)
History of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment
Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
Presence of significant subfoveal fibrosis or atrophy
Intraocular surgery (including cataract surgery) in the study eye within 2 months of enrollment
Active intraocular inflammation (grade trace or above) in the study eye
History of allergy to fluorescein, ICG or iodine, not amendable to treatment
Any concurrent intraocular condition in the study eye (e.g., cataract or diabetic retinopathy) that, in the opinion of the investigator, could either
Require medical or surgical intervention during the 12 month study period to prevent or treat visual loss that might result from that condition, or
If allowed to progress untreated, could likely contribute to loss of at least 2 snellen equivalent lines of BCVA over the 12 month study period
Prior/Concomitant Treatment:
Panretinal photocoagulation treatment
Previous intraocular steroids or PDT within 3 months
Previous participation in any studies of investigational drugs within 30 days preceding Day 0 (excluding vitamins and minerals)
Previous treatment with intravitreally (in either eye) or intravenously administered Avastin (bevacizumab) within 60 days
Previous use of Macugen or Lucentis in study eye within 60 days
Prior submacular or vitreous surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin J Blinder, MD
Organizational Affiliation
The Retina Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Retina Institute
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63017
Country
United States
Facility Name
The Retina Institute
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63128
Country
United States
Facility Name
The Retina Institute
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63144
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome
We'll reach out to this number within 24 hrs